Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions accepted — page 25

The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.

Submissions

735 documents · page 25 of 25

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-PRIMARY-VS-S/006Draft synthesis: Cardiovascular benefit in primary compared with…Dr Lorcan Zaleski-MbekiEfficacy outcomes are rated for certainty and harms are not
DRAFT-PRIMARY-VS-S/007Draft synthesis: Cardiovascular benefit in primary compared with…Eamon Sandringham-AduThe search date is not on the face of the document
DRAFT-PRIMARY-VS-S/009Draft synthesis: Cardiovascular benefit in primary compared with…Thaddeus Isaksen-BalogunOverlapping primary studies across included reviews are counted more than once
DRAFT-PRIMARY-VS-S/010Draft synthesis: Cardiovascular benefit in primary compared with…Anselm MountstephenThe search strategy as published cannot be re-run
DRAFT-TIRZEPATIDE-/001Draft synthesis: Tirzepatide compared with semaglutide in type 2…Dr Evander Ashworth-DanquahThe same concept is given three different names in one document
DRAFT-TIRZEPATIDE-/002Draft synthesis: Tirzepatide compared with semaglutide in type 2…Dr Oisín RautavaaraA continuity correction has been applied to zero-event arms without being reported
DRAFT-TIRZEPATIDE-/003Draft synthesis: Tirzepatide compared with semaglutide in type 2…Dr Ndidi Ravensworth-IlungaThe conclusion is stated more strongly than the certainty rating supports
DRAFT-TIRZEPATIDE-/004Draft synthesis: Tirzepatide compared with semaglutide in type 2…Bertrand Ollerenshaw industryTwo factual descriptions of the sponsor's programme are inaccurate
DRAFT-PEPTIDE-PURI/002Draft synthesis: Dependence of reported purity on the analytical…Dr Anselm Thorsby-NakamuraResults obtained by different methods are pooled without recording the method
DRAFT-MITOCHONDRIA/004Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Yaa KettlewellThe timepoint at which each outcome was extracted was chosen after the data were seen
DRAFT-MITOCHONDRIA/007Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Kolawole Isaksen-BalogunA continuity correction has been applied to zero-event arms without being reported
DRAFT-MITOCHONDRIA/009Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Leonhard QuennevilleDoses differing several-fold are pooled without examining dose-response
DRAFT-MITOCHONDRIA/010Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Thaddeus Isaksen-BalogunA single-trial result is presented in the visual form of a pooled estimate
DRAFT-MITOCHONDRIA/011Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Yusuf Whitmarsh-ObiRisk-of-bias judgements are reported as an overall rating without the domains
DRAFT-MITOCHONDRIA/012Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Dr Evander Ashworth-DanquahThe same concept is given three different names in one document

page 25 of 25

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.